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Signs & Symptoms 
CardioMEMS Heart Failure System: Keeping Patients out of the Hospital 
Michelle Leyland RN, BSN, BS  
Introduction 
     It is well known that heart disease is the 
leading cause of death in the United 
States, with about 670,000 new diagnoses 
of congestive heart failure (CHF) each year 
(Suh et al., 2011).  CHF results from a 
number of different causes, produces 
many different symptoms and occurs 
when the heart muscle cannot efficiently 
pump blood to the rest of the body (Suh et 
al., 2011).  In the United States, heart 
failure (HF) and associated hospitalizations 
are leading contributors to high health 
care costs (Feltner et al., 2014).  Up to one 
fourth of patients hospitalized with HF are 
readmitted within 30 days of discharge 
(Feltner et al., 2014).  In an effort to 
reduce expenditures for the Centers for 
Medicare & Medicaid Services (CMS), new 
policies have been created to help reduce 
readmission rates of HF patients (Feltner 
et al., 2014).  This has resulted in hospitals 
providing special HF education prior to 
discharge, HF coordinators, and HF clinics.  
In our age of technology, there have been 
many new innovations to help keep 
patients with HF out of the hospital and 
improve their quality of life.  Some include 
new medications, telemonitoring, and 
implantable devices.  The CardioMEMS HF 
System is a new device, recently approved 
by the U.S. Food and Drug Administration 
(FDA), which will optimistically prevent 
frequent hospitalizations for patients with 
HF (U.S. Food and Drug Administration 
[FDA], 2014).  According to the FDA 
(2014), the CardioMEMS HF System 
monitors patient’s pulmonary artery 
pressures (PAPs) and heart rate after a 
small, battery-free device is permanently 
implanted into the pulmonary artery.  The 
PA pressures and trends can be remotely 
reviewed by the physician, who can then 
adjust the patient’s medication regimen 
(FDA, 2014).  Thus far, the studies related 
to the CardioMEMS HF System have been 
very promising in keeping patients with HF 
out of the hospital and improving his or 
her quality of life. 
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    When blood is not adequately 
pumped out of the heart, the blood 
volume backs up into other areas of 
the body, such as the lungs or 
periphery.  When patients have 
left-sided heart failure, blood backs 
up into the pulmonary artery (PA) 
and lungs.  This results in 
pulmonary edema, which causes 
shortness of breath and even 
respiratory failure.  When the 
pressures in the PA are directly 
measured with the CardioMEMS HF 
device, clinicians can remotely 
monitor and proactively treat rising 
PAPs before patients present with 
symptoms related to 
decompensating HF (St. Jude 
Medical, Inc., 2014).  In turn, this 
keeps patients from being re-
admitted to the hospital for 
exacerbations.  Dr. Abraham (2014), 
at Ohio State University, states that 
the CardioMEMS heart failure 
system is beneficial for patients 
with systolic and/or diastolic heart 
failure.  The CHAMPION clinical 
trials for the CardioMEMS HF 
System showed a 28% reduction of 
hospital re-admissions after six 
months and a 37% reduction after a 
year (St. Jude Medical, Inc., 2014).    
     As the baby boomers continue to age, 
there will undoubtedly be an increase in 
the number of people living with CHF.  
While focus should remain on preventative 
care, education, and decreasing risk factors 
for developing HF, the goals of care will 
continue to be improving quality of life 
while providing cost-effective and 
evidence-based care (Smith, 2013).  
Patients with HF require frequent office 
and/or clinic visits for medication titration 
and symptom monitoring; however, 
disability, transportation, and cost could be 
barriers for compliance of these visits 
(Smith, 2013).  Patients with the 
implantable CardioMEMs HF System can be 
monitored from the comfort of their home 
and optimistically decrease hospitalizations 
related to HF symptoms.  As further 
research continues with medications, 
devices, and at the cellular level, the 
CardioMEMs HF System can safely improve 
the quality of life for patients with HF.   
Conclusion 
     It is inevitable that nurses will care for patients with some degree of CHF.  It is 
important for nurses to understand the pathophysiology of HF.  In doing so, nurses 
can better educate and treat patients.  In the hospital setting, nurses can screen 
patients for risks of re-admission and advocate for patients so they can receive 
available services at home (Smith, 2013).  Frazier et al. (2009) stress that clinicians 
should update their education on genetics and genetic testing as genetic discoveries 
related to HF are made.  Nurses play a pivotal role in the education of HF including 
medications, devices, diet and lifestyle changes.  The more patients understand 
their illness, the more likely they are to better manage their disease (Falk, Ekman, 
Anderson, Fu, & Granger, 2013).  In the case of the CardioMEMs HF System, the 
nurse should educate the patient on post-procedure care.  Because the clinician will 
be adjusting the patient’s medications regularly, it is important that the patient fully 
understands the medication(s).  It is also important that nurses provide emotional 
support and help patients with HF cope with the loss of independence, social 
isolation, and fear of the impending progression of his or her HF (Falk et al., 2013).       
Nursing Implications 
CardioMEMS HF System 
Depending on the type of myocardial 
dysfunction and the progression of the 
disease results in different signs and 
symptoms related to HF.  The New York 
Heart Association (NYHA) uses a four class 
system to classify symptoms and monitor 
progress (Nicholson, 2014).  The 
CHAMPION clinical trial studied patients 
with class III heart failure (St. Jude Medical, 
Inc., 2014).  Patients with class III HF have 
obvious limitations and excessive 
breathlessness, fatigue or palpitations 
(Nicholson, 2014).  Other clinical 
presentations of HF include orthopnea, 
nocturnal cough and dyspnea, peripheral 
edema, bloating, loss of appetite, 
confusion, angina, and syncope (Nicholson, 
2014).  Nicholas (2014) also lists signs that 
someone may have HF and might include 
tachypnea, tachycardia, irregular pulse, 
wheezing, weight changes, jugular venous 
distention (JVD), abnormal heart sounds 
such as a gallop or murmur, and pleural 
effusions.  These effects of HF are what 
limit patient’s activities of daily living and 
have been found to contribute to 
depression and a decreased quality of life.  
     The CardioMEMS HF system consists 
of a small, battery free sensor, an 
antenna, and a wireless electronics 
unit.  The sensor is permanently placed 
by a physician under fluoroscope into 
the PA via the femoral vein (St. Jude 
Medical, Inc., 2014).  The sensor cannot 
be felt and will not interfere with other 
implanted devices, such as a 
pacemaker; however, as with any 
invasive procedure, there are rare 
complications that can occur (St. Jude 
Medical, Inc., 2014).  Of note, 98.8% of 
patients in the clinical trial were free 
from complications related to the 
device (St. Jude Medical, Inc., 2014).  
Each morning the patient will take a 
few minutes to lay on a pillow 
containing the paddle-shaped antenna.  
The electronics unit will then read the 
patients PAPs and send them to a 
secure website that his or her doctor 
can access (St. Jude Medical, Inc., 
2014).  By directly measuring the 
pressures in the PA, physicians can 
adjust patients’ medications before 
they develop symptoms of worsening 
heart failure due fluid retention (Rose 
& Abraham, 2014).  This not only helps 
keep patients at home and out of the 
hospital, but it improves their quality of 
life (Rose & Abraham, 2014).  
     When the heart, or myocardium, cannot 
pump a sufficient amount of blood 
throughout the body, for whatever reason, 
it is simply termed congestive heart failure 
(CHF) (Suh et al., 2011).  However, CHF is a 
complex condition that involves the 
metabolic, neuroendocrine, and immune 
systems (Wrigley, Lip, & Shantsila, 2011).  
An abnormal heart muscle, or 
cardiomyopathy, can be categorized as 
primary or secondary, ischemic or non-
ischemic, and dilated, hypertrophic, or 
restrictive (Frazier, Wung, Sparks, 
Eastwood, 2009).  All of which may lead to 
CHF.  There are two main categories of HF, 
systolic and diastolic.  Depending on when 
in the cardiac cycle there is a deficiency, 
depends on the type of HF.  The heart can 
have difficulties during systole, when the 
heart muscle contracts and ejects blood 
from the heart out to the lungs and body, 
or during diastole, when the heart is at 
rest and the chambers are filling with 
blood (Suh et al., 2011).  There are 
additional classifications of left ventricular 
failure, right ventricular failure, or 
biventricular failure (Nicholson, 2014).  It is 
with left-sided heart failure when fluids 
back up into the pulmonary system, thus 
increasing the PAPs. 
     There are many pressures within the 
heart, vessels, and lungs that can be 
measured for diagnostic purposes.  As 
blood moves from the right ventricle into 
the pulmonary artery, the pressure is 
much lower than the blood pressure from 
the left ventricle into the aorta.  Normal 
systolic pressures in the pulmonary artery 
are less than 25 mm Hg and normal 
diastolic pressures are less than 10 mm Hg 
(Lancashire & South Cumbria Cardiac 
Network).  When PAPs rise, it could be 
caused by a number of factors, but for 
patients with HF, it is typically due to fluid 
overload.  Fluid and sodium intake need to 
be decreased and diuretics may need to be 
increased by the physician.  For patients 
with renal failure, they may need an extra 
dialysis treatment.   
   While some pathological causes of CHF 
may be reversible, such as infection and 
thyroid imbalances, many causes are not, 
such as hypertension and ischemic heart 
disease (Nicholson, 2014).  Coronary artery 
disease (CAD), a very common cause of 
CHF, results in coronary vessels becoming 
blocked or occluded.  
Heart tissue becomes ischemic and 
progresses to infarction and necrosis of 
the heart tissue resulting in HF.  In 
increased peripheral vascular resistance, 
or hypertension, the heart has to work 
harder to pump blood out of the heart.  
Like any muscle, the harder the muscle has 
to work, the larger it gets up to a certain 
point.  Frazier et al. (2009) describes 
cardiac remodeling as either hypertrophy 
or dilation.  Heart cells, or myocytes, 
change shape and increase in number to 
compensate (Frazier et al., 2009).   
     Perfusion is maintained by the 
compensatory changes of increased 
vasopressin, activation of the renin-
angiotensin-aldosterone system, and 
amplified adrenergic drive (Bergamini, 
Cicoira, Rossi, & Vassanelli, 2009).  These 
changes cause the kidneys to reabsorb a 
greater amount of water, thus increasing 
blood volume to increase blood pressure 
(Bergamini et al., 2009).  However, the 
increase in blood volume causes the heart 
chambers to stretch.  Along with chronic 
pressure overload, these neurohumoral 
stimuli are thought to contribute to the 
development of cardiac hypertrophy 
(Bergamini et al., 2009).  However, over 
time these compensatory mechanisms 
result in negative effects seen in chronic 
HF (Bergamini et al., 2009).  Once the 
myocardium stretches to the point where 
it cannot contract strongly, the heart fails 
to pump efficiently.        
     While there is still much research to be 
done, there is evidence that monocytes, 
inflammation, and oxidative stress play a 
role in the pathophysiology of HF.  Wrigley 
et al. (2011) report that inflammatory 
cytokines, such as tumor necrosis factor 
(TNF), are released in HF and are 
associated with LV dysfunction, 
remodeling, and myocyte apoptosis.  
When cardiac tissue is injured, monocytes 
help rid the body of necrotic tissue by 
phagocytosis and apoptosis (Wrigley et al., 
2011).  As inflammation continues, 
oxidative stress, which results when 
aerobic cells produce an excessive amount 
of reactive oxygen species (ROS), causes 
cellular damage and cardiac fibrosis 
(Bergamini et al., 2009).  When the heart 
tissue becomes fibrotic, or stiff, it cannot 
pump as forcefully.  Nitric oxide is also 
produced which results in weakened 
contraction of the myocardium (Wrigley et 
al., 2011).  
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Figure 1. Normal pressures in the 
heart and pulmonary artery. Adapted 
from Lancashire & South Cumbria 
Cardiac Network, n.d. 
Figure 2. Antenna and wireless electronics unit. 
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Figure 3. Adapted from St. Jude Medical, Inc., 
2014 
